CS
RCUS icon

Candriam SCA’s Arcus Biosciences RCUS Stock Holding History

Candriam SCA’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.1M Hold
790,613
– – 0.09% 213
2025
Q4 		$18.8M Buy
790,613
+412,172
+109% +$8.41M 0.09% 197
2025
Q3 		$5.15M Buy
+378,441
New +$3.93M 0.03% 365
2021
Q2 		– Sell
-408,991
Closed -$10.2M – 931
2021
Q1 		$10.2M Sell
408,991
-15
-0% -$522 0.08% 248
2020
Q4 		$10.6M Sell
409,006
-79,664
-16% -$1.93M 0.08% 252
2020
Q3 		$8.38M Buy
488,670
+265,728
+119% +$5.94M 0.08% 264
2020
Q2 		$5.51M Buy
+222,942
New +$6.02M 0.06% 313

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Candriam SCA's RCUS Position: Q1 2026 in Review

Candriam SCA held its Arcus Biosciences (RCUS) position steady in Q1 2026 at 790,613 shares worth $17.1M. The position accounts for 0.09% of the portfolio, ranked #213.

Candriam SCA first reported a position in RCUS in Q2 2020 and has held it in 7 quarters since. The position peaked at $18.8M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Candriam SCA held 790,613 shares of Arcus Biosciences worth $17.1M as of Q1 2026.
  • Candriam SCA left its Arcus Biosciences share count unchanged in Q1 2026.
  • Arcus Biosciences made up 0.09% of Candriam SCA's portfolio in Q1 2026, its #213 holding.
  • Candriam SCA first reported a position in Arcus Biosciences in Q2 2020 and has held it in 7 quarters since.
  • Candriam SCA's Arcus Biosciences position peaked at $18.8M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.